Diabetic ketoacidosis (DKA) is a life-threatening acute metabolic complication of diabetes mellitus, most frequently seen in type 1 diabetes but also occurring in type 2 diabetes under severe stress. When DKA develops in patients who also have chronic kidney disease (CKD), the clinical picture becomes considerably more complex. The kidneys play a central role in acid-base regulation, fluid balance, and the clearance of ketones. As kidney function declines, the typical signs of DKA can be blunted, masked, or paradoxically amplified. Healthcare providers must maintain a high index of suspicion and understand how CKD alters the presentation of DKA to ensure early recognition and prompt, effective treatment. This article provides a comprehensive overview of the signs of DKA in patients with CKD, the pathophysiology behind the altered presentation, diagnostic approach, and management considerations.

Understanding DKA and CKD: Pathophysiology and Intersection

Pathophysiology of Diabetic Ketoacidosis

DKA is triggered by an absolute or relative deficiency of insulin combined with an excess of counter-regulatory hormones such as glucagon, catecholamines, cortisol, and growth hormone. This hormonal imbalance leads to:

  • Hyperglycemia: Reduced glucose uptake in peripheral tissues and increased hepatic gluconeogenesis and glycogenolysis.
  • Ketogenesis: Accelerated lipolysis releases free fatty acids, which are converted to ketone bodies (acetoacetate, beta-hydroxybutyrate, and acetone) in the liver.
  • Metabolic acidosis: Accumulation of ketoacids overwhelms the bicarbonate buffer system, resulting in a high anion gap metabolic acidosis.
  • Osmotic diuresis: Hyperglycemia causes glucosuria and osmotic diuresis, leading to profound dehydration and electrolyte losses.

How CKD Alters the Pathophysiology of DKA

Chronic kidney disease introduces multiple overlapping disturbances that modify the classic DKA presentation:

  • Impaired renal acid-base regulation: The kidneys lose the ability to excrete acid efficiently (reduced ammoniagenesis and net acid excretion), making patients with CKD more susceptible to acidosis from any additional metabolic load.
  • Decreased ketone clearance: Renal excretion of ketone bodies is reduced as glomerular filtration rate (GFR) declines. This can lead to a more rapid rise in serum ketone levels, yet paradoxically, the classic fruity odor of breath may be less pronounced due to altered pulmonary excretion.
  • Fluid balance abnormalities: CKD patients often have baseline fluid overload, edema, and altered thirst response. The osmotic diuresis of DKA can be mitigated by the inability to excrete large volumes, but also can precipitate acute kidney injury on top of CKD.
  • Electrolyte disorders: Hyperkalemia is common in CKD due to reduced renal excretion, but DKA-induced acidosis shifts potassium out of cells, potentially causing life-threatening hyperkalemia. Conversely, after insulin therapy, rapid potassium shifts may lead to severe hypokalemia.
  • Anemia and delayed symptom perception: Fatigue and weakness from CKD may be mistaken for early DKA symptoms or vice versa.

Common Signs of DKA in CKD Patients

The classic signs of DKA—polyuria, polydipsia, weight loss, nausea, vomiting, abdominal pain, Kussmaul respirations, and altered mental status—may all be present but are often modified by CKD.

Kussmaul Respirations and Respiratory Compensation

Deep, rapid breathing (Kussmaul respirations) is the body’s attempt to compensate for metabolic acidosis by expelling carbon dioxide. In patients with CKD, the baseline acid-base status is often a mixed metabolic acidosis with a compensatory hyperventilation from chronic respiratory compensation. During DKA, the added acid load may push the respiratory drive to extremes. However, because the kidneys cannot excrete the daily acid load, the respiratory effort may be the primary compensatory mechanism. Observing an increased respiratory rate or a deep sighing pattern should immediately raise suspicion for DKA, especially in a known diabetic with CKD.

Gastrointestinal Symptoms: Nausea, Vomiting, Abdominal Pain

Nausea and vomiting occur in most DKA cases due to acidosis and dehydration. In CKD patients, these symptoms may be attributed to uremic gastropathy or medication side effects. Abdominal pain can be severe and mimic an acute abdomen. Delayed gastric emptying (gastroparesis) is common in both diabetes and CKD, and DKA exacerbates it. A healthcare provider must consider DKA in any diabetic CKD patient presenting with persistent nausea, vomiting, or epigastric pain, even if typical hyperglycemic symptoms are absent.

Altered Mental Status: From Confusion to Coma

Hyperosmolality, acidosis, and electrolyte derangements contribute to central nervous system depression. In CKD, uremic encephalopathy itself causes confusion, lethargy, and asterixis. When DKA supervenes, the mental status change may be more profound and occur at lower serum glucose levels than in patients with normal renal function. Because of reduced protective mechanisms, a CKD patient may slip into coma more quickly. Any acute change in cognition or level of consciousness warrants immediate assessment for DKA.

Fruity Breath and Hyperosmolar Signs

Acetone produces the characteristic fruity odor on the breath. However, in CKD, breath may already have a urinous or ammonia-like smell due to uremia. The fruity scent may be masked or interpreted differently. Additionally, hyperosmolar symptoms such as dry mucous membranes, poor skin turgor, and hypotension due to volume depletion may be less obvious if the patient is chronically fluid-overloaded in the interstitial space but intravascularly depleted. Look for tachycardia, orthostatic blood pressure changes, and decreased urine output (though oliguria may be already present due to CKD).

Fatigue and Weakness

Profound weakness is common in DKA from electrolyte depletion, acidosis, and dehydration. In CKD, fatigue is almost universal, but sudden worsening should be a red flag. Check for hypophosphatemia, hypomagnesemia, and potassium abnormalities, all of which can be exacerbated by DKA and further impair muscle function.

Atypical Presentations in CKD Patients

CKD often blunts the classic symptoms of DKA, leading to delayed diagnosis. Several atypical presentations are particularly important:

Euglycemic DKA in CKD

Patients with CKD who are on sodium-glucose cotransporter-2 (SGLT2) inhibitors are at increased risk for euglycemic DKA—DKA with blood glucose levels less than 200 mg/dL (11.1 mmol/L). The kidneys excrete glucose, reducing hyperglycemia, but ketogenesis continues. In CKD, reduced kidney function may further obscure the diagnosis because urine ketone tests may be unreliable and serum glucose is not dramatically elevated. Symptoms such as nausea, vomiting, and malaise can be easily mistaken for uremia or gastroenteritis. A high index of suspicion and measurement of serum beta-hydroxybutyrate are essential.

Hyperkalemic DKA

While classic DKA often presents with normal or mildly elevated potassium due to intracellular shifts, CKD patients may have significant hyperkalemia at baseline. The combination can result in dangerous cardiac arrhythmias. Conversely, the electrocardiographic changes of hyperkalemia (peaked T waves, widened QRS) may be the first clue to DKA if classic symptoms are absent.

Mixed Acid-Base Disorders

CKD patients often have a non-anion gap metabolic acidosis (from renal tubular dysfunction) or a normal anion gap acidosis from bicarbonate wasting. When DKA adds a high anion gap acidosis, the total acid load may be profound but the anion gap may not rise as high as expected because of impaired production of unmeasured anions or concomitant hyperchloremia. Careful interpretation of blood gas parameters is needed to recognize DKA superimposed on chronic metabolic acidosis.

Diagnostic Challenges and Key Laboratory Findings

Diagnosing DKA in CKD requires a thorough laboratory evaluation beyond simple glucose and urine ketones.

Essential Laboratory Tests

  • Serum glucose: Usually >250 mg/dL but may be lower in euglycemic DKA.
  • Serum ketones: Measure serum beta-hydroxybutyrate directly. Urine nitroprusside tests detect acetoacetate but not beta-hydroxybutyrate, and false positives can occur with drugs like captopril or valproic acid. In CKD, urine output may be low, making urine strips unreliable.
  • Arterial or venous blood gas: To assess pH, bicarbonate, pCO2, and calculate the anion gap.
  • Serum electrolytes: Including sodium, potassium, chloride, bicarbonate, blood urea nitrogen (BUN), creatinine, magnesium, phosphate.
  • Anion gap: Calculated as (Na+) − (Cl− + HCO3−). A gap >14–16 mEq/L is suggestive of DKA, but in CKD, the gap may be lower due to hypoalbuminemia (albumin carries negative charge). Correct the anion gap for albumin: corrected AG = AG + 2.5 × (4.5 − albumin in g/dL).
  • Osmolality: Serum osmolality may be elevated in DKA but in CKD, accumulation of urea contributes to measured osmolality, whereas effective osmolality (excluding urea) is a better marker of true dehydration.
  • Complete blood count and infection markers: Infection is a common precipitant of DKA; leukocytosis may be present.

Interpretation Nuances in CKD

The baseline serum bicarbonate in CKD patients is often chronically reduced (due to metabolic acidosis). A further drop can be subtle. Similarly, the BUN level is usually high from renal failure, so the ratio of BUN to creatinine may not rise as dramatically with dehydration. A non-elevated creatinine in DKA can reflect loss of muscle mass in CKD. Therefore, it is critical to compare current labs to the patient’s baseline values and look for acute changes beyond the chronic abnormalities.

External authoritative sources provide guidance: The National Kidney Foundation (KDIGO) comments on DKA management in CKD, and the American Diabetes Association Standards of Care include updated protocols for DKA including SGLT2 inhibitor-related euglycemic DKA.

Management Considerations for DKA in CKD

Treatment follows the same principles as standard DKA management but requires careful adjustments for renal impairment.

Fluid Resuscitation

Initial fluid deficit is usually 5–10% of body weight. However, CKD patients with reduced GFR are at risk for fluid overload if resuscitation is too aggressive. Use isotonic saline (0.9% NaCl) initially, but monitor urine output (if any) and signs of pulmonary edema. Switch to half-normal saline after volume repletion to avoid hyperchloremic acidosis. In anuric or oliguric patients, meticulous intake-output charts and central venous pressure monitoring may be needed.

Insulin Therapy

Regular insulin intravenously is standard. The dose does not require adjustment for renal function initially, but because CKD patients have reduced insulin clearance (kidneys degrade about 30–50% of endogenous insulin and exogenous insulin), the risk of hypoglycemia is higher. Frequent glucose monitoring (every 1–2 hours) is essential, and the insulin infusion may need to be decreased earlier than in patients with normal renal function once glucose starts to drop. Also, the correction of acidosis may be slower in CKD, requiring prolonged infusion.

Electrolyte Repletion

  • Potassium: If initial K+ is >5.5 mEq/L, defer replacement until after insulin and fluids lower it. Target 4.0–4.5 mEq/L. In CKD, hyperkalemia can be resistant to insulin alone; consider calcium gluconate for cardiac protection, and possibly sodium polystyrene sulfonate or patiromer if severe. Monitor for hypokalemia once acidosis corrects.
  • Phosphate: Replete if <1.5 mg/dL to avoid rhabdomyolysis or respiratory muscle weakness. CKD patients often have secondary hyperparathyroidism and may have high phosphate; repletion may not be needed.
  • Magnesium: Hypomagnesemia can cause hypokalemia and hypocalcemia; replace if low.
  • Bicarbonate: Routine use is controversial. In pH <6.9, consider cautious administration (1–2 amps of 8.4% sodium bicarbonate in 1 L 0.45% NS over 2 hours). In CKD, overzealous bicarbonate can cause volume overload and hypernatremia.

Treatment of Precipitating Factors

Common triggers include infection, myocardial infarction, stroke, noncompliance with insulin, and use of SGLT2 inhibitors. In CKD, infections are frequent and may be silent. Obtain cultures and imaging as indicated. Discontinue SGLT2 inhibitors during acute illness.

Transition to Subcutaneous Insulin

Once the patient is eating and anion gap closes, transition to subcutaneous insulin. Because of reduced renal clearance, longer-acting insulin doses may need to be reduced by 25–50% compared to standard protocols. Use multi-dose insulin regimens (basal-bolus) rather than sliding scale. Monitor blood glucose frequently and involve a nephrologist and endocrinologist if available.

Prevention Strategies

Prevention is paramount in patients with both diabetes and CKD. Key measures include:

  • Patient education: Teach patients to recognize early symptoms of DKA (nausea, fatigue, thirst) and have a sick-day plan. Emphasize never to stop insulin during illness even if eating poorly.
  • Monitoring during illness: Check blood glucose at least every 4 hours and test for ketones (serum beta-hydroxybutyrate preferred) when glucose >250 mg/dL or during any illness in a type 1 diabetic.
  • Adjust medications: In patients using SGLT2 inhibitors, discontinue the drug during acute illness, before surgeries, or when fasting. Do not start SGLT2 inhibitors in patients with GFR <30–45 mL/min/1.73 m² per guidelines.
  • Regular follow-up: Manage CKD aggressively with control of blood pressure, avoidance of nephrotoxins, and optimization of glucose and electrolytes. Regular testing of GFR, electrolytes, and acid-base status can detect early decompensation.
  • Coordination of care: Ensure communication between primary care, nephrology, and endocrinology teams. Clear protocols for emergency management can reduce delays.

Conclusion

Diabetic ketoacidosis in patients with chronic kidney disease presents a unique clinical challenge. The classic signs of DKA—rapid breathing, nausea, vomiting, abdominal pain, and altered mental status—may be attenuated, misinterpreted, or masked by the underlying uremia, fluid overload, and electrolyte disturbances. The risk of euglycemic DKA, severe hyperkalemia, and mixed acid-base disorders is increased. Early recognition relies on a high index of suspicion, careful history taking, and comprehensive laboratory assessment including serum beta-hydroxybutyrate and albumin-corrected anion gap. Management must be individualized, with careful attention to fluid volumes, insulin dosing, potassium handling, and the interplay of renal replacement therapy if needed. By understanding the modified pathophysiology and clinical presentation of DKA in CKD, healthcare providers can initiate timely treatment and improve outcomes for this vulnerable population. Refer to the NCBI review on DKA in renal impairment and CJASN article on DKA in CKD patients for further reading.